Results 201 to 210 of about 41,396 (291)

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

MedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang   +6 more
wiley   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao, Tingwen Xiang, Chuan Yang, Xiaohua Wang, Gang Huang, Fei Luo, Zhao Xie, Yueqi Chen   +7 more
wiley   +1 more source

Congenital CMV Infection: Determination of Transplacental Passage of Aciclovir by Ex Vivo Placental Perfusion

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 6, Page 1241-1248, May 2026.
ABSTRACT Objective To quantify the transplacental transfer of aciclovir at an amount equivalent to 2 g of valaciclovir corresponding to the fractionated dosing regimen given four times daily used to reduce congenital cytomegalovirus (CMV) transmission and to treat the CMV‐infected fetus. Design Experimental ex vivo study.
Helyett Ollivier, Valentine Faure Bardon, Leo Froelicher Bournaud, Isidore Gaubert, Tiffany Guilleminot, Marianne Leruez‐Ville, Jean‐Marc Treluyer, Yves Ville, Gabrielle Lui, Julien Stirnemann   +9 more
wiley   +1 more source

Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. [PDF]

Arch Virol, 2017
Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W.   +5 more
europepmc   +1 more source

Long‐Term Stress Adaptation as a Highly‐Conserved Key Factor in Yeast Aging

Aging Cell, Volume 25, Issue 5, May 2026.
This study shows that long‐term, but not short‐term, stress exposure triggers molecular changes in yeast that mirror established hallmarks of aging, including altered proteostasis, epigenetic shifts, and reduced lifespan. These changes are reversible upon stress removal, and the genes involved are conserved across all domains of life. ABSTRACT Aging is
Yanzhuo Kong, Damola Adejoro, Christopher Winefield, Stephen L. W. On, Philip A. Wescombe, Arvind Subbaraj, Andrew Saunders, Venkata Chelikani   +7 more
wiley   +1 more source

SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells. [PDF]

Sci Rep, 2017
Ordonez P, Kunzelmann S, Groom HC, Yap MW, Weising S, Meier C, Bishop KN, Taylor IA, Stoye JP.   +8 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

[124I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection [PDF]

, 2016
et al,, Siegel, Barry A
core   +2 more sources